A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007412/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.5 mg or 1
mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with
wearing-off phenomenon.
本研究旨在评估TVP-1012（每日给药0.5mg或1mg）作为左旋多巴辅助治疗方案，在伴有剂末现象的日本帕金森病受试者中的疗效与安全性。
提供机构：
Vivli
创建时间：
2021-09-22
